The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
16-Jan-12
$428 million
Target:
Robert Wiseman Dairies PLC
Acquiror:
Unternehmensgruppe Theo Müller
Advised Robert Wiseman Dairies PLC, the UK’s largest processor of fresh milk, on a recommended offer from Unternehmensgruppe Theo Müller S.e.c.s.
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
17-Oct-11
$630 million
Target:
Rebel Group Limited
Acquiror:
Super Retail Group
Advised Super Retail Group on the acquisition of Rebel Group Limited, Australia’s largest retailer of sporting goods, for A$610 million and the associated A$334 million capital raising used to fund the acquisition
27-Sep-11
$259 million
Target:
Goodman Fielder Limited
Advised Goodman Fielder Limited, an Australian consumer foods manufacturer and distributor, on its equity capital raising via a rights issue
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
13-Jun-11
$2.3 billion
Target:
The Timberland Corporation
Acquiror:
VF Corporation
Advised VF Corporation, a global leader in branded lifestyle apparel on its acquisition of The Timberland Company, a leading outdoor footwear and apparel company
13-May-11
$NA
Target:
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
13-Apr-11
$NA
Target:
Retail Apparel Group
Acquiror:
Navis Capital
Advised CHAMP Ventures on the sale of its portfolio company Retail Apparel Group, an Australian based men’s specialty apparel retailer, to Navis Capital, one of the largest regional private equity business in south-east Asia
11-Feb-11
$986 million
Target:
Findel plc
Advised Findel plc, a UK listed multi-channel retailer, on the restructuring of its balance sheet comprising an equity capital raising and refinancing of its debt and pension obligations
07-Feb-11
$548 million
Target:
Wesco Financial Corporation
Acquiror:
Berkshire Hathaway Inc.
Advised the Special Committee of Wesco Financial Corporation in connection with Berkshire Hathaway Inc.'s proposal to acquire the remaining 19.9% of the shares of Wesco’s common stock that it does not presently own
24-Dec-10
$NA
Target:
Tegel Foods Limited
Acquiror:
Affinity Equity Partners
Advised Pacific Equity Partners and ANZ, the shareholders of Tegel Foods (Tegel), on the sale of Tegel, New Zealand’s preeminent producer of poultry products, to Affinity Equity Partners
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
07-Dec-10
$500 million
Target:
Medicity, Inc.
Acquiror:
Aetna Inc.
Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
26-Aug-10
$622 million
Target:
Woolworths Limited
Advised Woolworths Limited, an Australian food and general merchandise retailer, on its A$704 million off-market share buy-back
12-Aug-10
$NA
Target:
Kohl’s Corporation
Acquiror:
Capital One Financial Corporation
Private Label Credit Card Business
Advised Kohl’s Corporation on a strategic alliance relating to its private label credit card business with Capital One Financial Corporation
12-Jul-10
$NA
Target:
Breast Care Business of Ethicon-Endo Surgery
Acquiror:
Devicor Medical Products, Inc. (a GTCR portfolio company)
Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery
05-Apr-10
$225 million
Target:
Medegen, Inc
Acquiror:
CareFusion Corporation
Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company
10-Mar-10
$576 million
Target:
Camelot Group plc
Acquiror:
Ontario Teachers’ Pensions Plan
Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan
25-Feb-10
$14.4 billion
Target:
Coca-Cola Enterprises Inc.
Acquiror:
The Coca-Cola Company
Advised the Affiliated Transaction Committee of Coca-Cola Enterprises Inc. on the sale of its North American bottling operations to The Coca-Cola Company and on its concurrent acquisition of The Coca-Cola Company’s bottling operations in the Nordic region
23-Feb-10
$NA
Target:
Heartscape Technologies, Inc.
Acquiror:
Roper Industries, Inc.
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company